This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent. OBJECTIVE: To review what is known about polymyxin B and to identify missing information or gaps for future investigations. METHODS: Pertinent information was reviewed from published literature in English. RESULTS/CONCLUSION: For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: